Abstract
Abnormal interactions of Zn2+ and Cu2+ with the amyloid β-peptide (Aβ) are proposed to play an important role in the neuropathogenesis of Alzheimer’s disease (AD). Metal chelators are potential therapeutic agents for AD because they could sequester metals ions from Aβ aggregates and reverse the aggregation. In this study, two nitrogencontaining ligands, TACN and BPA, have been investigated as possible metal chelators in the therapy of Alzheimer’s disease. The interactions between the chelators and Aβ40 aggregates are studied by turbidometry, thioflavin T (ThT) fluorescence spectroscopy, inductively coupled plasma mass spectrometry (ICP-MS), BCA protein assay, circular dichroism spectroscopy (CD), and atomic force microscopy (AFM). The results demonstrates that TACN and BPA are capable of both disrupting and preventing Zn2+ or Cu2+-induced Aβ40 aggregation. Moreover, they can also suppress the production of H2O2 induced by Cu-Aβ40, associated with toxic oxidative stress in AD.
Keywords: Alzheimer’s disease, Amyloid β-peptide, Metal, Chelators.
CNS & Neurological Disorders - Drug Targets
Title:Two Nitrogen-containing Ligands as Inhibitors of Metal-Induced Amyloid β-Peptide Aggregation
Volume: 13 Issue: 1
Author(s): Tingting Chen, Shajun Zhu, Siyuan Liu, Yapeng Lu and Li Zhu
Affiliation:
Keywords: Alzheimer’s disease, Amyloid β-peptide, Metal, Chelators.
Abstract: Abnormal interactions of Zn2+ and Cu2+ with the amyloid β-peptide (Aβ) are proposed to play an important role in the neuropathogenesis of Alzheimer’s disease (AD). Metal chelators are potential therapeutic agents for AD because they could sequester metals ions from Aβ aggregates and reverse the aggregation. In this study, two nitrogencontaining ligands, TACN and BPA, have been investigated as possible metal chelators in the therapy of Alzheimer’s disease. The interactions between the chelators and Aβ40 aggregates are studied by turbidometry, thioflavin T (ThT) fluorescence spectroscopy, inductively coupled plasma mass spectrometry (ICP-MS), BCA protein assay, circular dichroism spectroscopy (CD), and atomic force microscopy (AFM). The results demonstrates that TACN and BPA are capable of both disrupting and preventing Zn2+ or Cu2+-induced Aβ40 aggregation. Moreover, they can also suppress the production of H2O2 induced by Cu-Aβ40, associated with toxic oxidative stress in AD.
Export Options
About this article
Cite this article as:
Chen Tingting, Zhu Shajun, Liu Siyuan, Lu Yapeng and Zhu Li, Two Nitrogen-containing Ligands as Inhibitors of Metal-Induced Amyloid β-Peptide Aggregation, CNS & Neurological Disorders - Drug Targets 2014; 13 (1) . https://dx.doi.org/10.2174/18715273113129990076
DOI https://dx.doi.org/10.2174/18715273113129990076 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Responses of Glial Cells to Stress and Glucocorticoids
Current Immunology Reviews (Discontinued) Influence of Lithium Treatment on GDNF Serum and CSF Concentrations in Patients with Early Alzheimers Disease
Current Alzheimer Research VIP in Neurological Diseases: More Than A Neuropeptide
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
CNS & Neurological Disorders - Drug Targets Disease-Modifying Therapies in Frontotemporal Lobar Degeneration
Current Medicinal Chemistry The Role of AMPK/mTOR Modulators in the Therapy of Acute Myeloid Leukemia
Current Medicinal Chemistry “Tripping out” with the TRP Superfamily and TRPV1 for Novel Neuroprotection
Current Neurovascular Research Metabotropic Glutamate Receptors (mGluRs) and Diabetic Neuropathy
Current Drug Targets Converging Pathways in the Occurrence of Endoplasmic Reticulum (ER) Stress in Huntingtons Disease
Current Molecular Medicine Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development (Part B))
Current Pharmaceutical Design Genetic Markers in Biological Fluids for Aging-Related Major Neurocognitive Disorder
Current Alzheimer Research Pharmaceuticals and Cosmeceuticals Based on Soft Nanotechnology Techniques with Antioxidative, Immunostimulative and other Therapeutic Activities
Recent Patents on Nanotechnology Editorial (Thematic Issue: NAD<sup>+</sup> Biosynthesis and Signaling as an Emerging Area in Medicinal Chemistry)
Current Topics in Medicinal Chemistry Immunophilins: Structures, Mechanisms and Ligands
Current Molecular Pharmacology Commentary: Neurorestoratology: A Concept and Emerging Discipline in the Treatment of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Preface:
Current Topics in Medicinal Chemistry Nanoparticle-Mediated Drug Delivery: Blood-Brain Barrier as the Main Obstacle to Treating Infectious Diseases in CNS
Current Pharmaceutical Design Alterations in the Expression of Amyloid Precursor Protein Cleaving Enzymes mRNA in Alzheimer Peripheral Blood
Current Alzheimer Research Functional Roles of Benzothiazole Motif in Antiepileptic Drug Research
Mini-Reviews in Medicinal Chemistry Current & Future Therapies of Erectile Dysfunction in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued)